OXYGEN THERAPY
Phase 2Small molecule
OXYGEN THERAPY is one of 74 small molecule programs targeting Hernia. It is currently in Phase 2.
4
Indications
6
Total Trials
2
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
245 competitors in Kidney Disease
#DrugCompanyPhaseTrials
1Evrenzo
AstellasPhase 3
Zemplar
AbbViePhase 3
Reata
BiogenPhase 3
Victoza
Novo NordiskPhase 3
Invirase
RochePhase 3
Edarbi
TakedaPhase 3
Myfortic
NovartisPhase 3
Aranesp
AmgenPhase 3
Gazyva
RochePhase 3
Rituxan
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Complication1 trial
Kidney Disease1 trial
Oxygen Therapy in Diabetic Kidney Disease
Not yet recruiting·—·N/A·NCT06959485·80 enrolled
1 more indication
Oxygenation1 trial
Can High-Flow Oxygen Therapy Improve Oxygenation During Exercise in ILD Patients?
Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·N/A·NCT03287713·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OXYGEN THERAPY. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMassachusetts General Hospital